Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Patient-Centered Care for Chronic Diseases
share announcement

Patient-Centered Care for Chronic Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (10 April 2024) | Viewed by 7738

Special Issue Editor

Dr. Alberto Barcelo

E-Mail Website
Guest Editor
1. Epidemiology and Public Health, Department of Public Health Science, University of Miami School of Medicine, University of Miami, Miami, FL, USA
2. Department of Medical Clinic, University of Juiz de Fora, São Pedro, Minas Geais, Brazil
Interests: diabetes prevalence; cost of diabetes; diabetes care; diabetes management improvement; diabetes self-management education; diabetes mortality
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Care for a patient with chronic conditions cannot isolate the disease from the person, the family, and the community to ensure that patient mental and social needs are supported. Providers need to see patients as partners, since they tend to avoid taking measures they do not understand or are away from their reach. The current Special Issue aims to collect original articles as well as reviews relevant to patient-centered care.

Among others, this Special Issue aims to identify reports on chronic condition patient-centered care describing:

  • Healthcare facilities that define proactive programs and strategies focused on not only achieving patient clinical measures but also addressing mental, psychological, spiritual, and social wellbeing issues.
  • Healthcare organizations ensuring that patient needs are met by following up-to-date evidence-based clinical protocols, guidelines, and defined pathways integrating primary, secondary, and tertiary care.
  • Monitoring systems providing data for individual patient follow-up, practice evaluation, and supporting quality improvement strategies and care coordination.
  • Self-management programs empowering patients and families to achieve disease control and preventive goals.
  • Healthcare providers or organizations establishing links to community groups as well as churches, schools, and workplaces.

Dr. Alberto Barcelo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • patient-centered care
  • shared decision-making
  • evidence-based medicine
  • care pathway
  • care process
  • healthcare management
  • chronic condition

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1976 KiB  
Article
Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App
by Steffeni Papukchieva, Maria Kahn, Markus Eberl, Benjamin Friedrich, Natalie Joschko and Tjalf Ziemssen
J. Pers. Med. 2024, 14(4), 409; https://doi.org/10.3390/jpm14040409 - 12 Apr 2024
Viewed by 342
Abstract
Background: With a rising number of multiple sclerosis (MS) cases and increasing pressure on health systems, digital companion apps like Brisa, designed specifically for people with MS, can play an important role in the patient journey. These apps enable the collection of real-time [...] Read more.
Background: With a rising number of multiple sclerosis (MS) cases and increasing pressure on health systems, digital companion apps like Brisa, designed specifically for people with MS, can play an important role in the patient journey. These apps enable the collection of real-time longitudinal data that are critical to our understanding of the pathophysiology and progression of MS. Methods: This retrospective, descriptive analysis consists of data from Brisa users who registered between 6 August 2021 and 8 September 2022. Of the unique users, 37.7% (n = 1593) fulfilled the inclusion criteria including information about medication and demographics and tracked one or more symptoms and/or patient-reported outcomes. Users were classified as moderate-efficacy treatment users, high-efficacy treatment users and ocrelizumab users, and the reporting frequency and scores of symptoms and patient-reported outcomes were analyzed. Results: The largest cohort of Brisa users (405) reported treatment with ocrelizumab and were mostly diagnosed 2–5 years before the survey. The most reported MS symptoms were similar between OUs (ocrelizumab users), HETUs (high-efficacy treatment users) and METUs (moderate-efficacy treatment users). OUs on average reported symptoms and answered questionnaires more frequently. Baseline scores between HETUs and OUs were similar, whereas baseline scores of METUs were slightly lower in comparison. In a further analysis of OUs, disability scores increased with age; users aged 26–45 years had higher pain scores than 18–25-year-olds. No significant differences were found in quality of life, bowel control and vision between age groups. Conclusion: These findings show that the characteristics of the Brisa cohort are similar to the results of other studies and registries and can provide a representative overview of everyday disease management. Thereby, these results can bridge the gap between clinical research and real patient experience, but they also raise new questions, such as how often the hard-and-early therapy approach is already used and whether baseline characteristics and reasons for choosing a particular treatment contribute to the different outcomes over time. Answering these questions requires further research and analysis. Full article
(This article belongs to the Special Issue Patient-Centered Care for Chronic Diseases)
►▼ Show Figures

Figure 1

17 pages, 312 KiB  
Article
Nursing Care Plan for Patients with Tay–Sachs—A Rare Paediatric Disease
by Jonathan Cortés-Martín, Beatriz Piqueras-Sola, Juan Carlos Sánchez-García, Andrés Reinoso-Cobo, Laura Ramos-Petersen, Lourdes Díaz-Rodríguez and Raquel Rodríguez-Blanque
J. Pers. Med. 2023, 13(8), 1222; https://doi.org/10.3390/jpm13081222 - 01 Aug 2023
Viewed by 1691
Abstract
Tay–Sachs disease is classified as a rare paediatric disease of metabolic origin. It is an autosomal recessive inherited disease. The gene responsible for the disease is known as HEXA, and it is located on chromosome 15(15q23). There is currently no effective treatment for [...] Read more.
Tay–Sachs disease is classified as a rare paediatric disease of metabolic origin. It is an autosomal recessive inherited disease. The gene responsible for the disease is known as HEXA, and it is located on chromosome 15(15q23). There is currently no effective treatment for Tay–Sachs disease; hence, it is an incurable disease in which patients do not live for more than five years, meaning that nursing care takes on greater importance to maintain quality of life. The main objective of this work is to develop a specific standard nursing care plan by applying an inductive research method supported by nursing methodology using the NANDA-NIC-NOC taxonomy and validated by the Delphi method. This care plan will improve the knowledge of health professionals on this topic and support future studies on the disease. Following its implementation, the care plan proposed in this study aims to increase the quality of life of patients diagnosed with this disease. Full article
(This article belongs to the Special Issue Patient-Centered Care for Chronic Diseases)

Review

Jump to: Research

13 pages, 617 KiB  
Review
Advancing Patient Care: How Artificial Intelligence Is Transforming Healthcare
by Diana Gina Poalelungi, Carmina Liana Musat, Ana Fulga, Marius Neagu, Anca Iulia Neagu, Alin Ionut Piraianu and Iuliu Fulga
J. Pers. Med. 2023, 13(8), 1214; https://doi.org/10.3390/jpm13081214 - 31 Jul 2023
Cited by 8 | Viewed by 5240
Abstract
Artificial Intelligence (AI) has emerged as a transformative technology with immense potential in the field of medicine. By leveraging machine learning and deep learning, AI can assist in diagnosis, treatment selection, and patient monitoring, enabling more accurate and efficient healthcare delivery. The widespread [...] Read more.
Artificial Intelligence (AI) has emerged as a transformative technology with immense potential in the field of medicine. By leveraging machine learning and deep learning, AI can assist in diagnosis, treatment selection, and patient monitoring, enabling more accurate and efficient healthcare delivery. The widespread implementation of AI in healthcare has the role to revolutionize patients’ outcomes and transform the way healthcare is practiced, leading to improved accessibility, affordability, and quality of care. This article explores the diverse applications and reviews the current state of AI adoption in healthcare. It concludes by emphasizing the need for collaboration between physicians and technology experts to harness the full potential of AI. Full article
(This article belongs to the Special Issue Patient-Centered Care for Chronic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop